AfyaIndex
Kenyan Reference & Directory
Free lookups today: 2/3 · Unlimited with Pro Subscribe from KES 99
Free lookups: 2/3 Unlimited with Pro → Browse by class Interactions · Tip: type at least 2 letters, then pick a result

INN monograph

Moxifloxacin

Fluoroquinolone antibiotic · POM

POM Source-linked Grade A-

Source-linked · Updated 03 Aug 2026 · Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Fluoroquinolone antibiotic)

Kenya market

Wholesale / list prices where loaded

From
Median
Brands
0

Risk first

Contraindications

  • Hypersensitivity to quinolones.
  • History of quinolone-related tendon disorder.
  • Avoid in myasthenia gravis (exacerbation).
  • Generally avoid in children/adolescents except specific labelled indications.
  • Caution pregnancy/lactation — prefer alternatives when possible.

Precautions

  • Quinolones should be used with caution in children with a history of epilepsy or conditions that predispose to seizures, in G6PD deficiency, myasthenia gravis (risk of exacerbation).
  • Exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs).
  • Quinolones may induce convulsions in patients with or without a history of convulsions
  • taking NSAIDs at the same time may also induce them.
  • May cause arthropathy in the weight-bearing joints of immature animals and are therefore generally not recommended in children and growing adolescents.
  • However, the significance of this effect in humans is uncertain and in some specific circumstances short-term use of a quinolone in children is justified.
  • Should be avoid in pregnancy and lactation.

Point of care

Dosing

Adult

It may be given orally, or by intravenous infusion over 60 minutes. Usual dose is 400mg once daily.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Many agents need CrCl-based adjustment (e.g. ciprofloxacin, levofloxacin).

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

Hepatotoxicity uncommon but reported; moxifloxacin has more hepatic clearance.

Safety

Drug interactions

Open checker →
  • FDA boxed warning: moxifloxacin has been shown to prolong the QT interval of the ECG in some patients.
  • Moxifloxacin is key in the treatment of MDR-TB and in patients who are not able to tolerate the standard TB treatment regimen.

Safety

Adverse effects

  • GI disturbances, dizziness, headache, tremor, confusion, convulsions, rashes, blurred vision, psychotic reactions, impaired vision, impaired taste and smell sensation, stevens-johnson syndrome, hot flushes, skin rashes, migraine, photosensitivity.

Use

Indications

  • E.N.T., UTI, RTI, skin and soft tissues, bone, joint, GI, intra-abdominal, pelvic and severe infections, gonorrhea.
  • Clinical selection for Moxifloxacin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Fluoroquinolone antibiotic.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Pharmacology

Mode of action

Interferes with bacterial DNA synthesis by inhibiting topoisomerase II [DNA gyrase] and topoisomerase IV.

Inhibit DNA gyrase / topo IV Block replication Bactericidal
Full mechanism text

Interferes with bacterial DNA synthesis by inhibiting topoisomerase II [DNA gyrase] and topoisomerase IV. Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication and transcription. Bactericidal concentration-dependent killing with a post-antibiotic effect.

ADME

Pharmacokinetics & PD

Onset 1–2 hours oral
Duration 12–24 hours (agent-dependent)
Route ORAL / IV
Distribution including prostate and bone (agent-dependent). Renal and/or hepatic clearance varies by agent — adjust dose in organ impairment as labelled.
Full PK/PD text

Excellent oral bioavailability for most agents (near-IV for ciprofloxacin/levofloxacin in many settings). Wide tissue distribution including prostate and bone (agent-dependent). Renal and/or hepatic clearance varies by agent — adjust dose in organ impairment as labelled.

Kenya

Brands & prices

0 listed
Brand Company Pack KES
No brands linked yet.

Special populations

Pregnancy & lactation

Pregnancy

Generally avoid unless no safer alternative; animal arthropathy concerns and limited human data for many agents.

Lactation

Often avoided or used short-term with caution; check agent-specific guidance.

Diet

Food & alcohol

  • Food
  • Food

Trust

Sources & disclaimer

Source: Local active-ingredient clinical extract; RxNorm (NLM RxNav); PubChem; Professional class pharmacology (Fluoroquinolone antibiotic)

Open source link

Clinical review date not recorded.

Decision support only — not a substitute for clinical judgment, product SmPC, or Kenya STG/EML.

AfyaIndex dataset coverage